{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:28:19Z","timestamp":1747178899518,"version":"3.40.5"},"reference-count":37,"publisher":"Informa UK Limited","issue":"7","funder":[{"name":"no funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2021,7,3]]},"DOI":"10.1080\/14737140.2021.1921578","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T05:58:21Z","timestamp":1619071101000},"page":"689-692","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy and non-muscle-invasive bladder cancer: an idea from the 19th century"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5050-5232","authenticated-orcid":false,"given":"Eddy","family":"Lilly","sequence":"first","affiliation":[{"name":"Department of Hematology- Oncology, H\u00f4tel Dieu de France Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2006-8232","authenticated-orcid":false,"given":"Khalil","family":"El Gharib","sequence":"additional","affiliation":[{"name":"Department of Hematology- Oncology, H\u00f4tel Dieu de France Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"key":"cit0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00003086-199101000-00002","volume":"262","author":"Coley WB.","year":"1991","journal-title":"Clin Orthop"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.180037"},{"issue":"1","key":"cit0003","volume":"8","author":"Saginala K","year":"2020","journal-title":"Med Sci"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049"},{"key":"cit0005","unstructured":"Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder | British journal of cancer [Internet]. [cited 2021 Jan 21]. Available from: https:\/\/www.nature.com\/articles\/bjc2013372"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26002-6"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.6967"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0083"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.12.090"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.kjms.2015.05.005"},{"key":"cit0011","unstructured":"Bacille\u2010Calmette Gu\u00e8rin induces caspase\u2010independent cell death in urothelial carcinoma cells together with release of the necrosis\u2010associated chemokine high molecular group box protein 1 - See - 2009 - BJU International - Wiley online library [Internet]. [cited 2021 Jan 21]. Available from: https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/abs\/10.1111\/j.1464-410X.2008.08274.x"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.03.014"},{"key":"cit0013","doi-asserted-by":"crossref","unstructured":"Tumor necrosis factor-related apoptosis-inducing ligand | Cancer research [Internet]. [cited 2021 Jan 21]. Available from: https:\/\/cancerres.aacrjournals.org\/content\/64\/10\/3386","DOI":"10.1158\/0008-5472.CAN-04-0374"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.023"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-006-0112-0"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2014.15.3.1321"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110393"},{"key":"cit0019","unstructured":"Meeks J A phase 1 dose-escalation study of intravesical MK-3475 and bacillus calmette-guerin (BCG) in subjects with high risk and BCG-refractory non-muscle-invasive bladder cancer [Internet]. clinicaltrials.gov; 2020 Sep [cited 2021 Jan 21]. Report No.: NCT02808143. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02808143"},{"key":"cit0020","unstructured":"University of Oxford. A parallel group phase I\/II Marker Lesion study to assess the safety, tolerability and efficacy of intravenous or intravesical pembrolizumab in intermediate risk recurrent non-muscle invasive bladder cancer [Internet]. clinicaltrials.gov; 2020 Jul [cited 2021 Jan 21]. Report No.: NCT03167151. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03167151"},{"key":"cit0021","unstructured":"Merck Sharp & Dohme Corp. A phase 3, randomized, comparator-controlled clinical trial to study the efficacy and safety of pembrolizumab (MK-3475) in combination with bacillus calmette-guerin (BCG) in participants with high-risk non-muscle invasive bladder cancer (HR NMIBC) that is either persistent or recurrent following bcg induction or that is na\u00efve to BCG treatment (KEYNOTE-676) [Internet]. clinicaltrials.gov; 2020 Dec [cited 2021 Jan 21]. Report No.: NCT03711032. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03711032"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1263-z"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.2936"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.2936"},{"key":"cit0025","unstructured":"[Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study] - PubMed [Internet]. [cited 2021 Jan 22]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/2058066\/"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1159\/000324331"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.09.109"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.07.024"},{"key":"cit0029","unstructured":"AUA 2020: phase 3 results of vicinium in BCG-unresponsive non-muscle invasive bladder cancer [Internet]. [cited 2021 Apr 14]. Available from: https:\/\/www.urotoday.com\/conference-highlights\/aua-2020\/aua-2020-bladder-cancer\/122653-aua-2020-phase-3-results-of-vicinium-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer.html"},{"key":"cit0030","unstructured":"Open-label, multicenter, Ph 3 study to evaluate the efficacy and tolerability of intravesical viciniumtmin subjects with non muscle-invasive carcinoma in situ and\/or high-grade papillary disease of the bladder treated with BCG [Internet]. [cited 2021 Apr 14]. Available from: https:\/\/www.urotoday.com\/clinical-trials\/bladder-cancer\/96779-open-label-multicenter-ph-3-study-to-evaluate-the-efficacy-and-tolerability-of-intravesical-vicinium-in-subjects-with-non-muscle-invasive-carcinoma-in-situ-and-or-high-grade-papillary-disease-of-the-bladder-treated-with-bcg.html"},{"key":"cit0031","unstructured":"QUILT-3.032: a multicenter clinical trial of intravesical bacillus calmette-guerin (BCG) in combination with ALT-803 in patients with BCG unresponsive high grade non-muscle invasive bladder cancer - no study results posted - ClinicalTrials.gov [Internet]. [cited 2021 Apr 14]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03022825"},{"key":"cit0032","unstructured":"N-803 plus BCG elicits 72% CR in BCG-unresponsive, high-grade non-muscle invasive bladder cancer [Internet]. OncLive. [cited 2021 Apr 14]. Available from: https:\/\/www.onclive.com\/view\/n-803-plus-bcg-elicits-72-cr-in-bcg-unresponsive-high-grade-non-muscle-invasive-bladder-cancer"},{"key":"cit0033","unstructured":"SUO 2019: the SUO-CTC phase III adstiladrin\u00ae trial for BCG unresponsive non-muscle invasive bladder cancer [Internet]. [cited 2021 Apr 14]. Available from: https:\/\/www.urotoday.com\/conference-highlights\/suo-2019\/suo-2019-bladder-cancer\/117556-suo-2019-the-suo-ctc-phase-iii-adsiladrin-trial-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer.html"},{"key":"cit0034","unstructured":"Ferring Pharmaceuticals. A phase III, open label study to evaluate the safety and efficacy of INSTILADRIN\u00ae (rAd-IFN)\/Syn3) administered intravesically to patients with high grade, BCG unresponsive non-muscle invasive bladder cancer (NMIBC) [Internet]. clinicaltrials.gov; 2021 Mar [cited 2021 Apr 13]. Report No.: study\/NCT02773849. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02773849"},{"key":"cit0035","unstructured":"Research C for DE and. FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer. FDA [Internet]; 2020 Aug 1 [cited 2021 Mar 13]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer"},{"key":"cit0036","unstructured":"ASCO 2020: pembrolizumab for the treatment of patients with bacillus calmette-gu\u00e9rin unresponsive, high-risk non\u2013muscle-invasive bladder cancer: over two years follow-up of KEYNOTE-057 [Internet]. [cited 2021 Mar 13]. Available from: https:\/\/www.urotoday.com\/conference-highlights\/asco-2020\/asco-2020-bladder-cancer\/121866-asco-2020-pembrolizumab-pembro-for-the-treatment-of-patients-with-bacillus-calmette-guerin-bcg-unresponsive-high-risk-hr-non-muscle-invasive-bladder-cancer-nmibc-over-two-years-follow-up-of-keynote-057.html"},{"issue":"12","key":"cit0037","first-page":"1738","volume":"40","author":"Schiffmann J","year":"2014","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2021.1921578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,25]],"date-time":"2022-12-25T04:07:11Z","timestamp":1671941231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2021.1921578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7,3]]}},"alternative-id":["10.1080\/14737140.2021.1921578"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2021.1921578","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"type":"print","value":"1473-7140"},{"type":"electronic","value":"1744-8328"}],"subject":[],"published":{"date-parts":[[2021,5,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}